CORDIS
EU research results

CORDIS

English EN
Rheuma Tolerance for Cure

Rheuma Tolerance for Cure

Objective

In line with IMI2 goals for improved therapies and precision medicine, the aim of this proposal is to prevent and treat RA or its progression by inhibiting maturation/expansion of pathogenic autoimmune responses through immune tolerising treatments of subjects not only in early
stages of joint inflammation (undifferentiated arthritis and early RA) but also in even earlier defined stages i.e. before onset of joint inflammation, when patients have arthralgia and/or bone loss, or sub-clinical stages of joint inflammation.

Today, no drugs are approved for these early phases of RA development, where symptoms such as pain and fatigue cause major loss of life quality and where successful interference would prevent onset of disease. Thus, an important part of our work will be to achieve a better understanding of this as yet unexplored phase of disease. In the proposed project we will develop and validate new methods to identify individuals at high risk for RA, tools to monitor disease progress and expand and further develop cohorts suitable for these purposes.
Furthermore we will validate and standardise methods to monitor immune tolerance to be used in clinical trials for tolerising therapies for RA.
The aim is thus to interfere with the specific immune reactions that contribute to RA symptoms in such a way that a specific and long-lasting therapeutic effect (ultimately a cure) is accomplished for a major proportion of RA patients and prevention of diseases is accomplished in individuals at high risk for RA.

Investigator-initiated as well as company-sponsored clinical trials in well stratified patient groups will be performed in collaboration with SMEs and/or contributing pharma companies and their immune effects studied using the same panel of biomarkers allowing for standardisation across protocols. Our ambition is also to disseminate our experiences from RA to other rheumatic and other immune-mediated diseases.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

KAROLINSKA INSTITUTET

Address

Nobels Vag 5
17177 Stockholm

Sweden

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 190 000

Participants (19)

Sort alphabetically

Sort by EU Contribution

Expand all

Deutsches Rheuma-Forschungszentrum Berlin

Germany

EU Contribution

€ 465 000

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 465 000

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 465 000

THE UNIVERSITY OF BIRMINGHAM

United Kingdom

EU Contribution

€ 465 000

UNIVERSITATSKLINIKUM ERLANGEN

Germany

EU Contribution

€ 465 000

UNIVERSITY OF NEWCASTLE UPON TYNE

United Kingdom

EU Contribution

€ 465 000

UNIVERSITY OF GLASGOW

United Kingdom

EU Contribution

€ 465 000

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 595 000

THE UNIVERSITY OF QUEENSLAND

Australia

EU Contribution

€ 300 000

SEMMELWEIS EGYETEM

Hungary

EU Contribution

€ 180 000

APITOPE INTERNATIONAL NV

Belgium

EU Contribution

€ 240 000

ANOCCA AB

Sweden

EU Contribution

€ 240 000

FONDAZIONE PER L'ISTITUTO DI RICERC A IN BIOMEDICINA

Switzerland

JANSSEN PHARMACEUTICA NV

Belgium

UCB BIOPHARMA SPRL

Belgium

GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.

United Kingdom

SANOFI-AVENTIS DEUTSCHLAND GMBH

Germany

BRISTOL-MYERS SQUIBB COMPANY CORP

United States

PFIZER LIMITED

United Kingdom

Project information

Grant agreement ID: 777357

Status

Ongoing project

  • Start date

    1 September 2017

  • End date

    31 August 2022

Funded under:

H2020-EU.3.1.7.8.

  • Overall budget:

    € 13 846 865,50

  • EU contribution

    € 6 000 000

Coordinated by:

KAROLINSKA INSTITUTET

Sweden